SCHOTT Pharma expects revenues of 986.2 million euros for fiscal year 2025, representing an increase of 5.8% at constant currencies. EBITDA is expected to amount to 280.3 million euros, representing an increase of 11.5%. This corresponds to an EBITDA margin of 28.4%.
For fiscal year 2026, SCHOTT Pharma expects revenue growth at constant currencies in the range of 2-5% and an EBITDA margin of around 27%.
Based on this, SCHOTT Pharma updated its mid-term outlook for 2027 to 2029 to a revenue CAGR of 6-8% and expects the EBITDA margin to improve over the coming years towards 30%.
The full set of results for fiscal year 2025 will be published on December 11, 2025, at 07:00 a.m. CET.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.